The histone deacetylase inhibitor panobinostat lowers biomarkers of cardiovascular risk and inflammation in HIV patients
Anne Sofie Hogh Kolbaek Kjaer, Christel Rothe Brinkmann, Charles A Dinarello, Rikke Olesen, Lars Ostergaard, Ole Schmeltz Sogaard, Martin Tolstrup, Thomas Aagaard Rasmussen
AIDS | LIPPINCOTT WILLIAMS & WILKINS | Published : 2015
Awarded by NIH
The study was funded by the Institute of Clinical Medicine at Aarhus University, by The Danish Council for Strategic Research and by NIH Grant AI-15614 (to C.A.D.). Novartis provided panobinostat for the study.